SY-4835
Showing 1 - 25 of 49
Advanced Solid Tumor Trial in Shanghai (SY-4835)
Recruiting
- Advanced Solid Tumor
- SY-4835
-
Shanghai, Shanghai, ChinaRenji Hospital Affiliated to Shanghai Jiaotong University School
Mar 11, 2022
ADHD Trial in Worldwide (Guanfacine HCl (TAK-503), Atomoxetine HCl, Placebo)
Recruiting
- Attention Deficit Hyperactivity Disorder
- Guanfacine hydrochloride (TAK-503)
- +2 more
-
Dothan, Alabama
- +42 more
Aug 19, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in France, United States (SY-1425 (tamibarotene), azacitidine,
Active, not recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- SY-1425 (tamibarotene)
- +2 more
-
Hartford, Connecticut
- +25 more
May 4, 2022
NSCLC Trial in Shanghai (SY-5007)
Recruiting
- Non-Small Cell Lung Cancer
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Sep 4, 2023
Non Cystic Fibrosis Bronchiectasis Trial in Worldwide (Colistimethate Sodium, Saline Solution)
Completed
- Non Cystic Fibrosis Bronchiectasis
- Colistimethate Sodium
- Saline Solution
-
Adelaide, Australia
- +84 more
Aug 3, 2021
Sepsis Trial in Nanjing (SY-005, Placebo)
Recruiting
- Sepsis
- SY-005
- Placebo
-
Nanjing, Jiangsu, ChinaZhongda Hospital,Affiliated to Southeast University
Feb 27, 2022
Advanced Solid Tumor Trial in Beijing (SY-3505)
Recruiting
- Advanced Solid Tumor
-
Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Sep 15, 2023
Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)
Recruiting
- Non-small-cell Lung Carcinoma
-
Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
May 11, 2023
Galectin-9 in Rheumatoid Arthritis and Its Correlation With
Not yet recruiting
- Rheumatoid Arthritis
- (no location specified)
Jun 21, 2022
Acute Promyelocytic Leukemia Trial in United States (SY-2101, Arsenic Trioxide)
Recruiting
- Acute Promyelocytic Leukemia
- SY-2101
- Arsenic Trioxide
-
Birmingham, Alabama
- +4 more
Jul 12, 2022
Type 2 Diabetes Trial in China (SY-009 capsules)
Not yet recruiting
- Type 2 Diabetes
- SY-009 capsules
-
Bengbu, Anhui, China
- +6 more
Jun 17, 2022
Type 2 Diabetes Trial in Nanjing (SY-008, SY-008 matching )
Completed
- Type 2 Diabetes Mellitus
- SY-008
- SY-008 matching placebo
-
Nanjing, Jiangsu, ChinaNanjing Gulou Hospital
May 17, 2022
Dry Eye Disease Trial in Durham (SY-201 Ophthalmic Solution 2.0%, SY-201 Ophthalmic Solution 1.0%, SY-201 Ophthalmic Solution
Recruiting
- Dry Eye Disease
- SY-201 Ophthalmic Solution 2.0%
- +3 more
-
Durham, North CarolinaLexitas
Jul 27, 2022
Type 2 Diabetes Trial in China (SY-009, SY-009 matching )
Completed
- Type 2 Diabetes Mellitus
- SY-009
- SY-009 matching placebo
-
Hefei, Anhui, China
- +3 more
Mar 21, 2022
NSCLC Trial in Beijing (SY-3505)
Recruiting
- Non-small Cell Lung Cancer
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Mar 17, 2022
NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)
Recruiting
- Non-Small Cell Lung Cancer
- +2 more
-
Shanghai, Shanghai, China
- +1 more
Mar 17, 2022
Chronic Myelomonocytic Leukemia Trial in Houston (Azacitidine, Tamibarotene, Venetoclax)
Not yet recruiting
- Chronic Myelomonocytic Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2023
Mobile Applications Trial in Leuven (Recipes consumption, Hydroponic unit)
Enrolling by invitation
- Mobile Applications
- Recipes consumption
- Hydroponic unit
-
Leuven, Vlaams-Brabant, BelgiumDepartement Computerwetenschappen
May 26, 2023
Diabetic Eye Problems Trial in Shenyang (3% Diquafosol tetrasodium, 0.1% hyaluronate)
Not yet recruiting
- Diabetic Eye Problems
- 3% Diquafosol tetrasodium
- 0.1% hyaluronate
-
Shenyang, Liaoning, ChinaHe Eye Hospital
Jan 10, 2023
Coronavirus Infection, Sepsis Trial in London (recombinant human annexin A5, Placebo)
Recruiting
- Coronavirus Infection
- Sepsis
- recombinant human annexin A5
- Placebo
-
London, Ontario, CanadaLondon Health Sciences Centre
Apr 23, 2021
Advanced Solid Tumors, Ovarian Cancer, Breast Cancer Trial in Canada, France, United States (SY-1365 (Part 1), Carboplatin,
Terminated
- Advanced Solid Tumors
- +2 more
- SY-1365 (Part 1)
- +5 more
-
Birmingham, Alabama
- +19 more
Mar 5, 2021